Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though ...

KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, ...

KRAS and NRAS are members of the RAS family of genes, which encode proteins that regulate cell growth and division through ...

Explore Q1 2025 earnings insights from Edible Garden (EDBL): strategic pivots, gross margin growth, cost control, and the transformational ...

Good morning everyone and welcome to the Edible Garden AG Incorporated 2025 first quarter Business Update conference. At this time, all participants are in a listen-only mode and the floor will be ...

On May 8, the Food and Drug Administration granted accelerated approval to the combination of avutometinib and defactinib for ...

Revolution Medicines reports positive data for KRAS-targeting cancer drug elironrasib, showing higher response rates vs Amgen's Lumakras & Bristol Myers' Krazati ...

Treatment with the Avmapki Fakzynja Co-pack received accelerated FDA approval for previously treated low-grade serous ovarian ...

Sebi has launched an 'investor charter' for KYC Registration Agencies (KRAs) to detail services, investor rights, and ...

The FDA has granted accelerated approval to Avmapki (avutometinib) plus Fakzynja (defactinib) for the treatment of KRAS-mutated, recurrent low-grade serous ovarian cancer.

The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade ...